Radioactive treatment tested for prostate cancer recurrence
NCT ID NCT04206319
Summary
This study is testing whether Radium-223, a radioactive drug, can help men whose prostate cancer has returned but is only detectable through special PET scans, not standard imaging. Participants receive up to six monthly injections while researchers monitor changes in their immune system and PSA levels. The goal is to see if this treatment can control the cancer's progression with fewer side effects than hormone therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOCHEMICAL RECURRENT PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.